Invention Grant
- Patent Title: Substituted pyrrolopyrimidines as HDM2 inhibitors
-
Application No.: US14652466Application Date: 2013-12-18
-
Publication No.: US09637493B2Publication Date: 2017-05-02
- Inventor: Christopher Dinsmore , Francesc Xavier Fradera Llinas , Amit Ashokro Kudale , Michelle Machacek , Michael Hale Reutershan , Christopher Francis Thompson , B. Wesley Trotter , Liping Yang , Michael D. Altman , Stephane L. Bogen , Ronald J. Doll , Matthew E. Voss
- Applicant: Merck Sharp & Dohme Corp.
- Applicant Address: US NJ Rahway
- Assignee: Merck Sharp & Dohme Corp.
- Current Assignee: Merck Sharp & Dohme Corp.
- Current Assignee Address: US NJ Rahway
- Agent Yong Zhao; John C. Todaro
- International Application: PCT/US2013/075917 WO 20131218
- International Announcement: WO2014/100071 WO 20140626
- Main IPC: C07D487/04
- IPC: C07D487/04 ; A61K31/519 ; A61P35/00
Abstract:
The present invention provides substituted pyrrolopyrimidines of Formula I as described herein or a pharmaceutically acceptable salt or solvate thereof: The representative compounds are useful as inhibitors of the HDM2 protein. Also disclosed are pharmaceutical compositions comprising the above compounds and potential methods of treating cancer using the same.
Public/Granted literature
- US20150329548A1 SUBSTITUTED PYRROLOPYRIMIDINES AS HDM2 INHIBITORS Public/Granted day:2015-11-19
Information query
